Asian Journal of Pharmaceutical Sciences Volume 18, Issue 1 2023

Title	Asian Journal of Pharmaceutical Sciences Volume 18, Issue 1 2023
Edition	Volume 18, Issue 1 2023
Call Number
ISBN/ISSN
Author(s)
Subject(s)
Classification
Series Title
GMD	Jurnal
Language	English
Publisher	China Medical University
Publishing Year
Publishing Place	China
Collation
Abstract/Notes	a b s t r a c t Current treatments for advanced hepatocellular carcinoma (HCC) have limited success in improving patients’ quality of life and prolonging life expectancy. The clinical need for more efficient and safe therapies has contributed to the exploration of emerging strategies. Recently, there has been increased interest in oncolytic viruses (OVs) as a therapeutic modality for HCC. OVs undergo selective replication in cancerous tissues and kill tumor cells. Strikingly, pexastimogene devacirepvec (Pexa-Vec) was granted an orphan drug status in HCC by the U.S. Food and Drug Administration (FDA) in 2013. Meanwhile, dozens of OVs are being tested in HCC-directed clinical and preclinical trials. In this review, the pathogenesis and current therapies of HCC are outlined. Next, we summarize multiple OVs as single therapeutic agents for the treatment of HCC, which have demonstrated certain efficacy and low toxicity. Emerging carrier cell-, bioengineered cell mimetic- or nonbiological vehicle-mediated OV intravenous delivery systems in HCC therapy are described. In addition, we highlight the combination treatments between oncolytic virotherapy and other modalities. Finally, the clinical challenges and prospects of OV-based biotherapy are discussed, with the aim of continuing to develop a fascinating approach in HCC patients
Specific Detail Info
Image
File Attachment	LOADING LIST...
Availability	LOADING LIST...
	Back To Previous